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Background
Infection with human immunodeficiency virus infection
(HIV) is associated with an increased risk of Non Hodg-
kin’s lymphoma (NHL). There is limited data on the treat-
ment and outcome of these lymphomas in India. We
describe a retrospective study of 277 HIV infected patients
with NHL at a tertiary referral cancer center in Mumbai.
Material and methods
All patients included in this study were registered at the
HIV cancer clinic of the hospital during 2001-2010. All
patients were diagnosed to have NHL by tissue biopsy and
were confirmed by immunohistochemical tests. Patients
were staged with the Ann Arbor staging system. Data of
their demographic profiles, immune status, NHL stage,
treatment received, response and outcomes were analyzed.
We used the gender and age-specific proportion of NHL
of the year 2002 that was recorded in the Hospital Cancer
Registry to estimate an expected number of NHL among
HIV positive cancer patients during the period 2001-2010
(n=770) and the proportional incidence ratio (PIR) was
calculated.
Results
There were 277 patients during the ten year study period.
In males the PIR for NHL was 12.6 (95% CI 1.2-14.6) and
in females it was 22.1 (95%CI 17.1-28.3) .Among the 277
patients there were 69 females (24.9%) and 208 males
(75.1%). The median age of males was 38 years. In females
the median age was 37 years.100 Patients (36.1%) were
previously known to be HIV positive(range 6 mths-15
years).The CD4 count was less than 200 per cumm in
127/192 (66.14%) patients.76/277 (27.43% ) had current or
past history of tuberculosis. 172/277 (62%) patients had
extranodal involvement.
168/277 (60.64%) received cancer directed treatment .
The data of the 168 patients who received treatment was
analyzed. 91/134 (67.91%) had CD4 counts less than 200.
115/168 (68.45%) received antiretroviral therapy. 60% had
extranodal involvement.72 (42.9%) had DLCL, 42 (25%)
plasmablastic, 21(12.5%) Burkitt’s type and 31 (18.5%)
others.90/168 (53.6%) had advanced disease at presenta-
tion. All patients were treated with chemotherapy. 54
patients also received RT. The response was evaluated in
96 patients. There was complete response in 46 (47.9%),
partial in 15 (15.6%), stable in 6 (6.3%) and 29 (30.2%)
patients had progressive disease. The median survival was
25.3 months (range 0-56 months). ART affected survival
significantly; however age, sex, CD4 counts at presenta-
tion, histopathology, and presence of extranodal involve-
ment and stage of disease did not affect the survival.
Conclusions
In our study the PIR for NHL was high in HIV-infected
patients. The proportion of plasmablastic lymphomas is
high. The use of antiretroviral therapy has impacted the
overall survival.
Author details
1Department of Medicine, Tata Memorial Hospital, Mumbai, India.
2Department of Pathology, Tata Memorial Hospital, Mumbai, India.
Published: 19 April 2012
doi:10.1186/1750-9378-7-S1-P12
Cite this article as: Alahari Dhir et al.: HIV-associated non-Hodgkin’s
lymphoma- experience from a tertiary referral cancer center. Infectious
Agents and Cancer 2012 7(Suppl 1):P12. * Correspondence: arunaalahari@hotmail.com
1Department of Medicine, Tata Memorial Hospital, Mumbai, India
Full list of author information is available at the end of the article
Alahari Dhir et al. Infectious Agents and Cancer 2012, 7(Suppl 1):P12
http://www.infectagentscancer.com/content/7/S1/P12
© 2012 Dhir et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.